NEETPGAI
BlogPricing
Log inStart Free
NEETPGAI

AI-powered NEET PG preparation platform. Master all 19 subjects with adaptive MCQs, AI tutoring, and spaced repetition.

Product

  • Subjects
  • Pricing
  • Blog

Features

  • Adaptive MCQ Practice
  • AI Tutor
  • Mock Tests
  • Spaced Repetition

Resources

  • Blog
  • Study Guides
  • NEET PG Updates
  • Help Center

Legal

  • Privacy Policy
  • Terms of Service

Stay updated

© 2026 NEETPGAI. All rights reserved.
    Subjects/OBG/Endometriosis and Adenomyosis
    Endometriosis and Adenomyosis
    medium
    baby OBG

    A 38-year-old multiparous woman with a history of two prior cesarean sections presents with severe dysmenorrhea and chronic pelvic pain for 2 years. Transvaginal ultrasound shows diffuse thickening of the junctional zone (>12 mm) with heterogeneous echogenicity and no discrete adenomyotic lesions. Serum CA-125 is mildly elevated at 42 U/mL. She has completed 8 months of combined oral contraceptive therapy without symptom improvement. What is the most appropriate next step in management?

    A. Hysterectomy
    B. Diagnostic laparoscopy with endometrial biopsy
    C. MRI pelvis for further characterization and surgical planning
    D. GnRH agonist therapy for 6 months followed by add-back hormone therapy

    Explanation

    ## Clinical Scenario Analysis This patient has imaging-confirmed adenomyosis (diffuse junctional zone thickening) with severe symptoms refractory to first-line medical therapy. The clinical question is whether to escalate medical management or proceed to surgery. ## Why GnRH Agonist Is the Next Step **Key Point:** In women with adenomyosis who have failed COCs/NSAIDs, GnRH agonist therapy with add-back hormone replacement is the next medical escalation before considering hysterectomy. **High-Yield:** GnRH agonists suppress ovarian estrogen production and reduce endometrial proliferation, providing symptom relief in 60–80% of adenomyosis patients. Add-back therapy (estrogen ± progestin) prevents hypoestrogen side effects while maintaining efficacy. **Clinical Pearl:** Adenomyosis is a progressive disease of the myometrium; unlike endometriosis, it cannot be surgically excised. Hysterectomy is definitive but should be reserved for women who have exhausted medical options or desire permanent solution. ## Adenomyosis vs. Endometriosis: Management Differences | Feature | Endometriosis | Adenomyosis | |---------|---------------|-------------| | **Pathology** | Ectopic endometrial tissue outside uterus | Invagination of basalis endometrium into myometrium | | **Imaging hallmark** | Ovarian cysts, peritoneal nodules | Junctional zone thickening (>12 mm) | | **First-line therapy** | NSAIDs + COCs | NSAIDs + COCs | | **Second-line therapy** | Laparoscopy + excision OR GnRH agonist | GnRH agonist ± add-back | | **Definitive therapy** | Hysterectomy (if fertility not desired) | Hysterectomy | | **Surgical role** | Diagnostic and therapeutic | Limited; mainly for diagnosis confirmation | **Tip:** Remember: **Endometriosis → Laparoscopy**; **Adenomyosis → Medical escalation then Hysterectomy**. ## Rationale Against Other Options ```mermaid flowchart TD A[Adenomyosis + Failed COCs]:::outcome --> B{Next step?}:::decision B -->|Laparoscopy| C[Not diagnostic for adenomyosis]:::urgent B -->|MRI| D[Useful for diagnosis, not treatment]:::action B -->|GnRH agonist + add-back| E[Symptom relief in 60-80%]:::action B -->|Hysterectomy| F[Premature; medical options remain]:::urgent E --> G{Response?}:::decision G -->|Yes| H[Continue or consider progestin-IUD]:::action G -->|No| I[Hysterectomy if fertility complete]:::action ``` [cite:Park 26e Ch 18; ACOG Committee Opinion on Adenomyosis]

    Practice similar questions

    Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.

    Start Practicing Free More OBG Questions